The global live cell encapsulation market is projected to reach $286.5M by 2030, registering a CAGR of 3.97% during the forecast period, according to a report by Grand View Research.
Increasing adoption of live cell encapsulation in regenerative medicine, rising public-private investments in cell & gene therapies, and the growing significance of live cell encapsulation for therapeutic purposes are key factors driving the industry. Furthermore, major advantages associated with live cell encapsulation of a drug or treatment system include easy administration, the possibility to control the accurate release rate of a drug over time, and the provision of desired, pre-programmed drug release anticipated to boost the industry growth over the study period. Increasing public-private funding & investments in cell and gene therapies are projected to drive the market during the forecast period.
Key Findings:
- The natural polymers segment held the largest share in 2022 owing to its advantages, such as low toxicity, renewability, biocompatibility, flexibility to modification, and biodegradability.
- The microencapsulation method segment accounted for the largest share in 2022 due to the benefits offered by microencapsulation, including pre-programmed drug-release profiles, easy administration, and the ability of the technique to control the release rate of a fused drug over periods (hours to months).
- The drug delivery application segment dominated the industry in 2022 owing to the potential application of drug delivery to treat various diseases, such as cancer, tuberculosis, diabetes, and rheumatoid arthritis, in the form of tablets, capsules, or parenteral dosage forms.
- North America held the largest revenue share in 2022. The large share can be attributed to established healthcare infrastructure, increased per capita healthcare expenditure, and rising funding & investments in cell and gene therapies space in the region.